CASRN: 209860-87-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of tafluprost during breastfeeding. Because of the extremely low levels in plasma after application to the eye, it is not likely to reach the breastmilk or bloodstream of the infant or to cause any adverse effects in breastfed infants. Professional guidelines consider prostaglandin eye drops acceptable during breastfeeding.[1-3] To further diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Belkin A, Chen T, DeOliveria AR, et al. A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma 2020;3:79-89. [PubMed: 32672600]
- 2.
- Blumen-Ohana E, Sellem E. Pregnancy & glaucoma: SFO-SFG recommendations. J Fr Ophtalmol 2020;43:63-6. [PubMed: 31813552]
- 3.
- Kumari R, Saha BC, Onkar A, et al. Management of glaucoma in pregnancy - balancing safety with efficacy. Ther Adv Ophthalmol 2021;13:25158414211022876. [PMC free article: PMC8243098] [PubMed: 34263134]
Substance Identification
Substance Name
Tafluprost
CAS Registry Number
209860-87-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antiglaucoma Agents
Prostaglandins
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: February 15, 2025.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Tafluprost. [Updated 2025 Feb 15].